Please login to the form below

Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.

CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs).

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal Cell Carcinoma (RCC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN). 

Find out more 
https://www.researchpartnership.com/news/2017/06/therapy-watch-expands-oncology-and-ibd-portfolios/


5th July 2017

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Live webinar: Optimise your digital assets with UX research
Thursday 25th October 2018 11:00 EDT / 16:00 BST / 17:00 CEST
Research Partnership
Rare diseases and orphan drugs: Our experience and expertise

Research Partnership
Conducting research for publication video

Research Partnership
Conference research case study
How conference research was used to gauge reactions to new clinical data and measure the impact of a company’s presence at a leading industry event
Research Partnership
Portfolio analysis: Using market research to master communications across a therapeutic category

Research Partnership
EphMRA round up 2018
EU Directors Angela Duffy, Richard Head and Dan coffin attended the EphMRA annual conference in Basel.
Research Partnership